Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients
initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several …

EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of
treatment with EGFR-inhibitors, such as erlotinib. Multiple resistance mechanisms have …

Introduction Mesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in
non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations. In …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …

Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …

Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) is a critical
problem in the treatment of lung cancer. Although several mechanisms have been shown to …

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR)
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …

Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-
mutant non-small cell lung cancer (NSCLC) eventually develop acquired resistance to …

BACKGROUND: Epithelial-to-mesenchymal transition (EMT), which was related with an
acquired resistance to gefitinib, was found in the A549 lung cancer cell line. However, the …

Objective The epithelial to mesenchymal transition (EMT) is associated with acquired
resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in …